Biomanufacturing’s digital transformation faces significant integration hurdles

Fragmented systems, disconnected data, and a lack of digital maturity remain major challenges, according to panelists at MilliporeSigma’s Life Science Innovation Summit.

While biopharmaceutical companies are implementing digital strategies that include artificial intelligence (AI), automation, and connected systems, they are facing challenges in integrating these platforms into their manufacturing operations.

That’s the consensus of panelists from ElevateBio, GSK, and Siemens who participated in a discussion on the future of biomanufacturing at MilliporeSigma’s 2026 Life Science Innovation Summit, held Tuesday in Burlington, Massachusetts.

Sebastian Arana, head of process solutions at MilliporeSigma and moderator of the panel, observed that companies are prioritizing their digital investments to improve quality control and optimize processes, as they try to keep pace with an industry that is changing rapidly.

“In the last few years, the biomanufacturing space has changed a lot,” said Arana, with multi‑modal manufacturing — the ability to produce different therapy types in the same facility — becoming critical for biopharma companies as their pipelines diversify. He also pointed to obstacles that must be overcome to successfully transfer a product or process from one location to another, as well as mounting cost reduction and lead‑time pressures.

Still early in the digital journey     

Biomanufacturing is at an inflection point as biopharma companies pursue digital transformation to lower production costs through smarter, more efficient processes and faster time-to-market in an increasingly competitive landscape. Digital twins, predictive maintenance, and real-time quality monitoring are being leveraged at varying levels of implementation to minimize downtime, reduce waste, and improve batch consistency.

MilliporeSigma CEO Jean-Charles Wirth in a separate session at Tuesday’s summit told the audience that AI and digitalization “run through everything we do.” Wirth noted that the company in 2025 extended its strategic partnership with Siemens to accelerate digital transformation in the life science industry, focusing on integrated software solutions, systems, and consumables that leverage AI, automation, and data.

However, a Rockwell Automation report last month found that although more than half of life science manufacturers (58%) have deployed smart manufacturing technologies — either at scale or across portions of their operations — many are navigating common challenges around data accessibility, system integration, governance, and operational complexity. 

While 90% of life science manufacturers say digital transformation is now business-critical, the report revealed that only 32% of organizations effectively use more than half of the data they collect, making it harder to scale technologies like AI which rely on connected, trusted, and contextualized data. For many manufacturers, AI adoption has outpaced governance, infrastructure, and organizational readiness.

At the same time, persistent hurdles are holding back progress in scaling these digital initiatives, according to Tuesday’s panel. The panelists said fragmented data, limited interoperability between manufacturing systems, and uneven digital maturity are barriers to success.

Jared Haas, industry strategy for pharma/biotech and material sciences at Siemens, observed that systems are often disconnected and manual, with manufacturers operating Laboratory Information Management Systems, Manufacturing Execution Systems, and Quality Management Systems in silos causing inconsistent records and delayed investigations.

“How are they stitching it all together? Excel spreadsheets — and, that is not connected data,” Haas commented.

Kimberly Mattia, director of manufacturing sciences and technology (MSAT) and new product introduction at GSK’s Upper Merion, Pennsylvania campus, said her team is “leading a lot of the digital transformation that’s happening right now [at the site], integrating all of the different technologies together that really don’t talk very well.”

To help remedy the problem, GSK is investing $1.2 billion in AI and digital technologies in five manufacturing sites in four states — Maryland, Montana, North Carolina, and Pennsylvania — including the construction of a new “biologics flex factory” in Upper Merion.

“The biggest thing that we’re thinking about is how to build it from the ground up,” said Mattia, whose team is responsible for more than 90% of the data analysis from all the commercial manufacturing products at the Upper Merion site. “A lot of our systems are antiquated. They’re 30 years old. We built them ourselves, so we have to piece all those together. We get the chance to restart and think about how to build it so that all of the systems are speaking to each other in the right way.”

A tale of two facilities at ElevateBio

With $1.3 billion in funding, contract development and manufacturing organization ElevateBio has an established cGMP manufacturing facility in Waltham, Massachusetts, with a second site under construction in Pittsburgh, Pennsylvania as it looks to expand the company’s cell and gene therapy production capacity.

Founded in 2017, ElevateBio claims that “through continuous investment in automation, AI, and next-generation technologies” it will be able to provide the “quality, speed, and scale” its customers will need to bring advanced therapies to more patients.

For clinical and commercial manufacturing, the Waltham facility operates multiple segregated suites for cell therapy products, mRNA, and viral vectors, while leveraging automated systems for real-time review of process data and release of product.

By comparison, the Pittsburgh facility — which is expected to open in 2027 — has been designed from the start to incorporate automation, digital manufacturing technologies, and end-to-end cGMP capabilities to support large-scale production of advanced therapies.

“Our sister site in Pittsburgh is launching as a fully digital end-to-end manufacturing site with the intention to be entirely focused on reducing cost of goods,” said Katie Jorgensen, site head for cell and gene therapy manufacturing at ElevateBio’s Waltham facility.

In Waltham, Jorgensen said ElevateBio is evaluating different AI tools and agents to draft protocols and make batch manufacturing more efficient by standardizing daily unit operations.

“We’re capturing data from each cell therapy batch to be able to analyze that as a holistic dataset,” she explained. “We’re looking at different tools to do that analysis. We work with a lot of companies that are early phase, so starting that data capture early is helping us set process control strategies for later. All of that’s manual right now, so we’re trying to find and work on digitizing that internally.”

Jorgensen added that what ElevateBio learned from the Waltham site in designing the new Pittsburgh facility is “connecting those systems earlier instead of having standalone, independent systems.” 

About the Author

Greg Slabodkin

Editor in Chief

As Editor in Chief, Greg oversees all aspects of planning, managing, and producing the content for Pharma Manufacturing’s website and digital products, as well as the daily operations of its editorial team.

For more than 20 years, Greg has covered the healthcare, life sciences, and medical device industries for several trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing.

When not covering the pharma manufacturing industry, he is an avid Buffalo Bills football and Buffalo Sabres hockey fan, likes to kayak, and plays guitar.

Sign up for our eNewsletters
Get the latest news and updates